Tejaswi Kanala MD

RadOnc | Fellow @MDAndersonNews | @RadOncTMC, OsmaniaMed alum | @CanGenetics_TMC | Organ preservation & Radiobiology | opinions my own |

[Tejaswi Kanala MD @TSKanala]

Radiation Oncology 101 this #NEETPG season for the uninitiated med student. Most MBBS grads in India come across #RadOnc for the very first time when preparing for NEETPG & a 4 hour lecture doesn't cut what we do in our sacred basements. Here is a primer to help you choose. 1/n

[Erman Akkus @Erman_Akkus]

Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial @OncoAlert https://t.co/fiFLKKhBYV

[Muhammad Ali @dr_alimuhammad]

Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years.

https://t.co/07jeA1lQMb

[Ethan Ludmir MD @ebludmir]

Trials already underway! The role of local therapy for mPDAC in the RASi era is only just beginning… @NiuSanford @DrShubhamPant @ACKoongMDPhD @PrajnanDasMD @Vince_BernPag @eugenekoay @ChadTangMD

[Tejaswi Kanala MD @TSKanala]

A pioneer!
‘Not Taking “No” for an Answer’ is an interesting and inspiring read about her journey in her own words.
https://t.co/L7xJZYiuDU

[Dr. Cathy Eng @CathyEngMD]

I just learned #cancer #surgical icon of the #nonoperativemanagement approach to #rectalcancer Dr. Angelita Habr-Gama just passed away today at the age of 93. She was AMAZING! She has changed our views on the necessity of surgery in the setting of cCR. #groundbreaking #cancerresearch #originaldisruptor

[Tejaswi Kanala MD @TSKanala]

Congratulations @Anil_Tibdewal !

[Eric K. Singhi, MD @lungoncdoc]

Deferring brain RT appeared “safe”overall:
•mOS 28.7 vs 23.3 mos
���HR 1.45, p=0.07

However, nearly HALF of pts in the delayed RT arm ultimately required salvage brain RT within 2 yrs (48% vs 21%).

Delayed RT patients more likely to need WBRT at progression (68% vs 54%)
#ASCO26

[Vanita Noronha, MBBS MD DM @VanitaNoronha]

Proud to share ph III RCT on low-dose abiraterone (250 mg w/food) vs std-dose abi in CRPC.
Despite markedly lower drug exposure, low-dose abi had comparable efficacy, safety & QoL: supporting affordable and practical treatment https://t.co/hHmmLxM4hl
#ProstateCancer @OncoAlert

[Vedang Murthy @VedangMurthy]

A personal story published today in the @TataMemorial Newsletter

Radiation after Cystectomy in Bladder Cancer (the BART trial): A Timeless Problem, A Timely Solution

Read Here:
https://t.co/bchheXlCU2

[Nandan Nilekani @NandanNilekani]

Introducing the Samvardhan Biodiversity and Conservation Fellowship — a 12-month Fellowship co-curated by Rohini Nilekani Philanthropies and Dasra, and seed funded by @RNP_Foundation, built to support the next generation of conservation leaders across India, especially those from grassroots communities and underrepresented regions.

Too many passionate conservationists leave the field not because they lose interest, but because the system doesn't support them. The Samvardhan Fellowship is here to change that.

What the fellowship offers:
- A seed grant of ₹3 lakh for practice-led conservation work
- Mentorship from conservation experts throughout the year
- Peer learning through cohort sessions, knowledge workshops, and community building

Who can apply:
- Early-career conservation researchers and practitioners under 35, engaged in public-interest conservation — whether in research, fieldwork, or community work.
- Applicants from diverse educational backgrounds and non-elite institutions are strongly encouraged. _(Note: PhD students are not eligible.)_

Applications are open now! Visit https://t.co/0FR75pzTd3 to apply.

[Charles Jiang MD, MPH @CharlesJiangMD]

14/The stakes are arithmetic. Full-dose pembro runs to six figures a year. This group's own framing: approved regimens reach 1–3% of patients in low- and middle-income countries.
There, dose is the entire access lever.

[Charles Jiang MD, MPH @CharlesJiangMD]

15/Why is this underestimated? Look at who's incentivized to shrink a dose.
The people who sell it have no reason to. De-escalation trials come from public hospitals and academics. The most important pricing experiment in oncology is run by the people with the least $.

[Priyamvada Maitre @docpriyamvada]

🤩 Finally OUT in @JCO_ASCO!

BART RCT from 🇮🇳 largest ph3 for adjuvant RT in high risk MIBC post cystectomy

A decade of persistence from @VedangMurthy ☺️
@RadOncTMC @TataMemorial @ACTREC_TMC
@PaulSargos
@Xristodouleas

https://t.co/B8iTgImLHr

[Vedang Murthy @VedangMurthy]

Is SBRT (36.25 Gy/5#) non-inferior to MHRT in high-risk & N+ prostate cancer?

526 patients, 3 centres, mpMRI + PSMA staging, 77% whole-pelvis RT.

Largest RCT in this population. From @TataMemorial @RadOncTMC 🔥
#ESTRO2026

[TMC Radiation Oncology @RadOncTMC]

@ESTRO_RT @JifmiM @dr_samdavid @AnuradhaaKrish @Dr_ArunimaNagar @Supriya_Sastri @VedangMurthy @DrVasanthapriya @Suman_radonc @ReenaEngineer @AshwiniBudrukar Proffered Paper at ESTRO 2026

Dr @ReenaEngineer from GI Oncology @RadOncTMC present DEROP-RC, a prospective phase II study of MR-guided HDR endorectal brachytherapy boost for organ preservation in locally advanced rectal cancer.

#ESTRO2026 #RectalCancer #Brachytherapy #RadOnc

[TMC Radiation Oncology @RadOncTMC]

@ESTRO_RT @JifmiM @dr_samdavid @AnuradhaaKrish @Dr_ArunimaNagar @Supriya_Sastri @VedangMurthy @DrVasanthapriya @Suman_radonc @ReenaEngineer @AshwiniBudrukar Proffered Paper at ESTRO 2026

Dr Tejpal Gupta from Team NEuro Oncology @RadOncTMC presented outcomes of de-escalated radiotherapy with low-dose CSI followed by chemotherapy in low-risk WNT-pathway medulloblastoma.

#ESTRO2026 #Medulloblastoma #PaediatricOncology #RadOnc

[Giulia Marvaso @GiuliaMarvaso84]

One of the standout talks of #ESTRO2026 👏 'A lot to be proud of'
@alison_tree brilliantly highlighted how modern #RadOnc in #PCa is evolving beyond technology alone , with increasing focus on continenze, sexual function and QoL alongside outstanding cancer control!

[Alexander Sherry @AlexSherryMD]

1/ Tremendous thanks to the patients, coauthors and all who made the EXTEND trial possible. The primary aggregated analysis is now available online @JCO_ASCO with ctDNA correlatives presented synchronously at @ESTRO_RT #ESTRO26

[Joe Y Chang @JoeChangMD]

When I was a resident 24 years ago, we were taught that renal cancer is radiation resistant disease. Now, we learn that RT can achieve up to 100% local control when RT dose is appropriate.

[ilyas sahin, MD @ilyassahinMD]

New @JCO_ASCO * analysis of ~5,000 HCC patients treated with external beam radiation therapy across 30 centers in 11 countries.

Median overall survival:
-BCLC-0 (very early stage, a single tumor 2 cm or smaller): 6.8 years
-BCLC-A (early stage, single tumor of any size or up to 3 tumors ≤3 cm each): 4.6 years
-Treatment-naive BCLC-A: 5.4 years

Retrospective, but the scale is striking. EBRT belongs in the frontline HCC discussion.

[Albert Koong, MD PhD @ACKoongMDPhD]

Congrats @ChadTangMD @AlexSherryMD @ebludmir on this seminal work which changes our approach to oligometastatic disease. Bravo! @UTMDAnderson #radonc #endcancer

https://t.co/mGOJ5BhPm0

[Simona F. Shaitelman MD, EdM @SFShaitelmanMD]

Honored to present data #MakingCancerHistory on ablative radiation and omission of surgery on behalf of the Exceptional Responder Study Group at #ESTRO26 @ESTRO_RT @MDAndersonnews with @RO_GreenJournal concurrent publication mentored by @HenryKuerer